Lorazepam
Viewing r1.a1 — Oct 2, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Lorazepam — also known as Ativan — is a synthetic depressant of the benzodiazepine class. It is a high-potency relative of diazepam, distinguished by a metabolic pathway that bypasses liver oxidation and produces no active metabolites.[1] Lorazepam is a positive allosteric modulator of GABA-A receptors, producing its effects by amplifying inhibitory signaling throughout the central nervous system.[2][3]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
benzodiazepines, ethanol, phenobarbital +2 morebenzodiazepines, ethanol, phenobarbital, barbiturates, Z-drugs show less
Synthesized in 1963 by Stanley C. Bell, lorazepam was FDA-approved in 1977 and became one of the most widely prescribed benzodiazepines globally.[4] IV lorazepam is established as first-line treatment for status epilepticus,[5][6] though recent scholarship revealed that foundational alcohol-withdrawal trials were ghostwritten by its manufacturer.[4] It remains widely available under brand names including Ativan, Temesta, and Tavor.
Subjective effects include anxiety suppression, sedation, anterograde amnesia, muscle relaxation, and emotional suppression. The experience is one of broad quieting — cognitive activity decelerates, emotional reactivity flattens, and physical tension dissolves into a heavy, indifferent calm that can feel unremarkable even as impairment deepens. Disinhibition, delusions of sobriety, and compulsive redosing are characteristic unsought effects.
Lorazepam produces rapid physical dependence and ranks among the benzodiazepines with the highest withdrawal severity,[7] though death from the compound alone is extremely rare.[8] Tolerance develops within days of continuous use;[9][10] co-administration with opioids carries an FDA Black Box Warning for increased overdose mortality.[11] Six decades of clinical data and extensive pharmacological research provide a well-characterized safety profile.
History[edit]
History
Discovery
Lorazepam was synthesized in 1963 by Stanley C. Bell at American Home Products Corporation (later Wyeth Pharmaceuticals), part of the wave of benzodiazepine research that followed Leo Sternbach's discovery of chlordiazepoxide in the 1950s.[12][4] Bell introduced two structural innovations over diazepam: a 3-hydroxy group enabling direct glucuronidation without liver oxidation, and a 2'-chloro substituent on the phenyl ring that increased binding potency.[12] These changes addressed diazepam's limitations — its long-acting metabolite and dependence on CYP450 metabolism — yielding a compound with a cleaner pharmacokinetic profile.
Clinical adoption and controversy
The FDA approved Ativan (lorazepam) on September 30, 1977 for short-term anxiety relief.[4][12] Clinical use expanded rapidly into status epilepticus, alcohol withdrawal, procedural sedation, and ICU care, and in 2001 the PHTSE trial established Level A evidence for IV lorazepam in prehospital seizure termination.[5][6] However, three 1983–1984 trials declaring lorazepam the "drug of choice" for alcohol withdrawal were later revealed to have been ghostwritten by Wyeth Pharmaceuticals, concealing adverse outcomes including breakthrough seizures — current evidence favors Diazepam or chlordiazepoxide for alcohol withdrawal in patients without liver impairment.[4]
Modern use
The 2011 RAMPART trial demonstrated that intramuscular midazolam was noninferior to IV lorazepam for prehospital status epilepticus, shifting prehospital protocols toward midazolam for its practical advantage of intramuscular administration.[13] Lorazepam remains one of the most widely prescribed benzodiazepines worldwide, available as a generic under brand names including Ativan (US/Canada), Temesta (Europe), Tavor (Germany/Italy), and Orfidal (Spain).[12]
The name "lorazepam" follows standard benzodiazepine nomenclature, with the "-azepam" suffix identifying the 1,4-benzodiazepine class. Its most recognized trade name, Ativan, became so widely used in clinical settings that it functions as a near-synonym for the compound itself. Lorazepam occupies a distinctive role in hospital culture as a frontline emergency sedative — frequently the first benzodiazepine reached for in acute agitation and status epilepticus.
Chemistry[edit]
Chemistry
Structural class
Lorazepam belongs to the 1,4-benzodiazepine chemical class, built on the fused benzene-diazepine bicyclic scaffold shared by diazepam, clonazepam, and alprazolam. Two structural features set it apart from most classical benzodiazepines: a 3-hydroxy group on the diazepine ring, shared with oxazepam and temazepam; and a 2'-chloro substituent on the pendant phenyl ring at position 5.[12]
The 3-hydroxy group is the pharmacokinetically decisive feature — it provides a direct substrate for phase II glucuronidation, allowing the drug to bypass the CYP450 oxidative metabolism required by diazepam and most other benzodiazepines.[1][3] The 2'-chloro substituent increases binding affinity at the benzodiazepine site, contributing to lorazepam's high potency relative to its parent scaffold.[12]
Molecular properties
| Molecular formula | C₁₅H₁₀Cl₂N₂O₂ |
| Molecular weight | 321.2 g/mol |
The molecule consists of the 1,4-benzodiazepine core bearing a chlorine at position 7, a 2-chlorophenyl group at position 5, a hydroxyl at position 3, and a lactam carbonyl at position 2. The commercial form is achiral — while the 3-hydroxy group introduces a potential stereocenter, the marketed product exists as the racemic mixture or equilibrated form, with no clinically relevant stereoisomer differentiation.[12]
Physical properties
Lorazepam is a white to off-white crystalline powder with moderate lipophilicity.[14] It is sparingly soluble in water; injectable formulations require propylene glycol (approximately 80% by weight) and polyethylene glycol 400 as co-solvents.[15]
Pharmacology[edit]
Pharmacology
Mechanism of action
Lorazepam is a positive allosteric modulator of GABA-A receptors — the brain's primary inhibitory receptor system.[3][2] It binds to a site at the interface between α and γ₂ subunits on the GABA-A receptor, distinct from where GABA itself binds. Rather than activating the receptor directly, lorazepam increases the frequency of chloride channel opening when GABA is present, amplifying the brain's own inhibitory signals.[3][2]
Lorazepam is a full agonist at this site — it produces maximal enhancement of GABA activity, unlike partial agonists that produce submaximal effects.[16] It binds non-selectively across GABA-A subtypes containing α1, α2, α3, and α5 subunits.[2] Different subunit types mediate different effects: α1 subunits contribute to sedation and amnesia; α2 and α3 subunits drive anxiolysis and muscle relaxation; α5 subunits modulate learning and memory.[2]
Pharmacokinetics
Oral bioavailability is near-complete (~90–100%), with peak plasma levels reached approximately 2 hours after ingestion.[17][3] Sublingual and intramuscular routes achieve comparable absorption (94–98% and 89–96%, respectively).[17][18]
Despite rapid absorption into the bloodstream, lorazepam enters the brain more slowly than diazepam. EEG effects after IV administration peak approximately 30 minutes post-infusion — a delay attributed to slower passage across the blood-brain barrier.[19] This slow brain equilibration explains why oral onset feels gradual and can prompt premature redosing.
The half-life is 10–20 hours (mean ~14 hours).[1][17][20][3] Lorazepam is metabolized exclusively by direct glucuronidation, producing a single inactive metabolite — lorazepam glucuronide.[1][18][3] It does not interact with cytochrome P450 enzymes, giving it a clinically important advantage in drug interaction potential over benzodiazepines like Diazepam, midazolam, and alprazolam.[1][3]
Neuroscience[edit]
Neuroscience
Where it acts
Lorazepam amplifies inhibitory signaling across nearly every brain region containing GABA-A receptors. In the cortex, this enhanced inhibition slows motor output and psychomotor processing.[21] In the hippocampus, receptors containing the α5 subunit are disproportionately affected, producing the pronounced anterograde amnesia that is a signature feature even at lower doses.[2]
In the amygdala, enhanced GABA activity dampens fear and threat responses, producing anxiolysis.[3] Reduced prefrontal executive control underlies the disinhibition observed alongside anxiety relief. In reward-relevant circuits, lorazepam has confirmed reinforcing properties — self-administration studies in primates demonstrate abuse potential driven by α1-containing receptor activation.[22]
Why tolerance develops
Continuous lorazepam exposure triggers a cascade of adaptive changes at the GABA-A receptor. Within days, the receptor's coupling to its chloride channel weakens — the drug still binds, but its ability to enhance GABA diminishes.[9] Simultaneously, the brain reduces production of key receptor components and destabilizes the scaffolding that anchors receptors at synapses.[10]
As the inhibitory system downregulates, excitatory glutamate signaling ramps up as a homeostatic counterbalance.[10] This glutamatergic rebound effect drives the hyperexcitability — including seizure vulnerability — that emerges during withdrawal. Cross-tolerance with alcohol occurs because both substances act on the same GABA-A receptor system.[9][23]
Several fundamental questions about lorazepam remain unresolved despite decades of clinical use. The molecular basis for its slow blood-brain barrier penetration — despite lipophilicity similar to diazepam — has not been fully characterized.[19] Paradoxically, lorazepam impairs formation of new memories while enhancing recall of material presented before administration in elderly subjects,[24] through an unknown mechanism.
Subjective Effects[edit]
Subjective effects
Lorazepam produces an experience defined by broad suppression — cognitive, emotional, and motor functions are uniformly dampened rather than selectively altered. The experiential character shifts markedly with baseline state: individuals in acute distress report pronounced calm and relief, while non-anxious users encounter the same dose primarily as sedation and cognitive blunting. Higher doses deepen amnesia and motor impairment in a relatively linear fashion, with the transition from anxiolysis to heavy sedation occurring without a clear qualitative shift.
Within the benzodiazepine class, lorazepam sits between diazepam (longer-acting, faster brain entry, more commonly described as euphoric) and alprazolam (faster onset, shorter duration, stronger compulsive redosing urge). Its profile is most comparable to oxazepam — both are 3-hydroxy benzodiazepines with no active metabolites — though lorazepam is substantially more potent and produces more prominent amnesia.
Effect Grid
Clear anxiety suppression and moderate sedation dominate the experience. Emotional suppression is pronounced — worries, fears, and emotional reactivity feel significantly blunted. Thought deceleration is obvious, with reduced analytical capacity and focus suppression. Anterograde amnesia becomes measurable, lasting up to 6 hours — users may not recall conversations or activities during this window.
Muscle relaxation is pronounced. Motor control impairment manifests as noticeable ataxia and slowed reaction time. Physical fatigue and dizziness are common. Appetite enhancement may emerge.
Disinhibition and delusions of sobriety are particularly significant at this range — users feel more functional than they objectively are, creating risk for driving, decision-making, and compulsive redosing.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Sleep-transition hallucinations · Visual haze / noise · Visual processing suppression
Bodily heaviness · Dizziness · Breathing alteration · Heart rate perception changes · Nystagmus (eye wobbles) · Laughter fits · Nausea · Restlessness
Nystagmus (eye wobbles) · Laughter fits · Nausea · Restlessness
Cognitive fatigue · Memory suppression · Thought deceleration · Analysis suppression · Memory fragmentation · Motivation suppression · Language suppression · Suggestibility enhancement · Confusion · Thought disorganization · Humor enhancement · Compulsive redosing urge · Amnesia · Delirium
Analysis suppression · Memory fragmentation · Motivation suppression · Language suppression · Confusion · Thought disorganization · Humor enhancement · Compulsive redosing urge · Amnesia · Delirium
Craving · Sociability suppression
Timeline
Subtle shift in anxiety level that may be imperceptible due to lorazepam's slow blood-brain barrier penetration. Some users notice a faint easing of tension; others detect nothing until the come-up phase.
Gradual anxiolysis emerges alongside mild sedation and muscle relaxation. Thought deceleration begins. The slow build can prompt premature redosing — wait at least 90 minutes before considering dose adjustment.
Full anxiolysis, sedation, anterograde amnesia, motor control impairment, and disinhibition. Delusions of sobriety are most prominent here — subjective function feels preserved while objective impairment is significant.
Sustained effects at slightly reduced intensity. Amnesia continues through this phase. Sedation and muscle relaxation remain pronounced while anxiolysis persists.
Gradual return of baseline anxiety and motor function. Residual sedation and cognitive slowing persist. Some users notice the first hints of rebound anxiety during late resolution.
Residual drowsiness and mild cognitive impairment. Some users report the onset of rebound anxiety. The 10-20 hour elimination half-life means subclinical impairment outlasts subjective effects.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- rapid
- Tolerance reset
- 11 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- benzodiazepines · ethanol · phenobarbital
Toxicity
Acute toxicity
Lorazepam has a high therapeutic index relative to older sedative drugs. In studied cases of deliberate overdose, all patients recovered within 24–30 hours despite very high blood levels, and the body's ability to eliminate the drug was not impaired at toxic concentrations.[8] Death from lorazepam alone — without other substances — is extremely rare.
The primary life-threatening risk in acute exposure is respiratory depression, which worsens dramatically when combined with opioids, alcohol, or other depressants.[3] Respiratory and cardiac complications were the most commonly encountered serious adverse events in clinical trials of IV lorazepam for status epilepticus.[6]
Propylene glycol toxicity
The injectable formulation contains propylene glycol (approximately 80% by weight) as a solvent.[15] With prolonged high-dose IV infusion — typically in ICU settings — propylene glycol accumulates and can cause metabolic acidosis and kidney damage.[25] Oral formulations do not contain propylene glycol.[3]
Common adverse effects
Sedation, dizziness, poor coordination, anterograde amnesia, confusion, fatigue, double vision, slurred speech, constipation, and urinary retention are documented at therapeutic doses.[3] Paradoxical agitation and disinhibition occur occasionally, particularly in elderly patients and those with brain injury.[3]
Pregnancy and elderly
Lorazepam is classified as FDA Pregnancy Category D — evidence of fetal risk exists.[3][26] Third-trimester use is associated with neonatal sedation, breathing difficulty, weak feeding, and withdrawal symptoms persisting hours to months after birth.[26]
In elderly patients, lorazepam is classified as potentially inappropriate per the Beers Criteria due to increased fall risk, cognitive impairment, and excessive sedation.[3]
Psychological risks
Anterograde amnesia is dose-dependent and can last up to 6 hours — users may engage in activities during the amnestic window with no subsequent recall.[27] This risk compounds with disinhibition: impaired judgment combined with absent memory creates conditions for harmful behavior the user cannot later reconstruct.
Delusions of sobriety — feeling capable and functional while objectively impaired — are a consistent class effect.[3] Users may attempt driving, complex decisions, or further dosing while significantly impaired.
Compulsive redosing is reported as a class effect: anxiolysis, amnesia, and disinhibition create conditions where additional doses are taken without awareness of cumulative exposure.
Rebound anxiety and insomnia after discontinuation contribute to the cycle of dependence even following short-term therapeutic use.[10]
Tolerance and dependence
Tolerance develops within days of continuous use for anxiolytic, anticonvulsant, and sedative effects.[3][10] Animal models confirm functional tolerance at 7 days of continuous exposure,[9] with anticonvulsant tolerance documented at 14 days.[28] Cross-tolerance with alcohol and other benzodiazepines is well-established.[9][23]
Dependence liability is high. Lorazepam ranks among benzodiazepines with the highest withdrawal severity, alongside alprazolam and triazolam.[7][10]
Withdrawal features include anxiety, insomnia, tremor, sweating, rapid heartbeat, sensory hypersensitivity, and in severe cases, generalized seizures and delirium.[10] Standard management involves substitution with a long-acting benzodiazepine (typically diazepam) and gradual dose taper.[10][3]
Drug interactions
Opioids: The FDA has issued a Black Box Warning for concurrent use. Co-prescription increases overdose death risk by 40–334%.[11][3] Both drug classes suppress breathing independently; combined use narrows the margin between a therapeutic and lethal dose.
Alcohol: Ethanol and lorazepam share the same mechanism (GABA-A potentiation), producing additive sedation, breathing suppression, and aspiration risk.[3]
Other depressants: Barbiturates, other benzodiazepines, and Z-drugs (zopiclone, zolpidem) produce additive sedation and respiratory depression.[3]
IV formulation + metronidazole: The propylene glycol vehicle can trigger a disulfiram-like reaction.[3]
CYP450 independence: Lorazepam's bypass of liver oxidation enzymes means it has minimal pharmacokinetic drug interactions — a significant advantage over CYP450-metabolized benzodiazepines.[1][3]
Reversal agent: Flumazenil reverses all CNS effects of lorazepam at the receptor level. In chronically dependent patients, flumazenil precipitates acute withdrawal.[3] Its duration of action is shorter than lorazepam's, so resedation may occur and monitoring is essential.[3]
Contraindications
Absolute:
- Hypersensitivity to lorazepam or other benzodiazepines[3]
- Severe breathing difficulties (unless mechanical ventilation is available)[3]
- Acute narrow-angle glaucoma[3]
- Sleep apnea[3]
Relative:
- Pregnancy, especially first and third trimester[3][26]
- Active substance use disorder (except medically supervised detoxification)[3]
- Elderly patients — Beers Criteria classification as potentially inappropriate[3]
- Concurrent opioid therapy — FDA Black Box Warning[3]
- Liver disease with encephalopathy — while metabolism is preserved, enhanced brain sensitivity may worsen encephalopathy[29]
Harm Reduction[edit]
Forms & Identification
Pharmaceutical lorazepam is widely available as generic tablets in standardized strengths (0.5 mg, 1 mg, 2 mg), typically embossed with manufacturer-specific markings. The primary identification concern is distinguishing genuine pharmaceutical tablets from counterfeit or pressed pills, which may contain no lorazepam, variable doses, or entirely different substances.
Reagent testing has limited utility for benzodiazepines — standard field kits (Marquis, Mecke, Mandelin) do not reliably identify lorazepam. Immunoassay-based benzodiazepine test strips confirm the presence of a benzodiazepine but cannot distinguish lorazepam from other compounds in the class. Fentanyl test strips should be used on any tablet of uncertain provenance.
Guidelines
- Start with the lowest effective dose and wait at least 2 hours before considering whether effects are sufficient
- Do not drive, operate machinery, or make important decisions after taking lorazepam — impairment persists even when subjectively feeling sober
- Secure medications and valuables before dosing; amnestic disinhibition can lead to unintended redosing or poor decisions
- If prescribed, take as directed and discuss any desire to increase dose with a prescriber rather than self-adjusting
- Do not stop abruptly after more than a few days of continuous use — withdrawal can cause seizures
Set & Setting
Lorazepam's slow brain entry creates a deceptive onset — the drug may take 30–60 minutes to produce noticeable effects orally, and the full impact may not arrive for 2 hours. The most common harm-related error is redosing during this window under the assumption the first dose was insufficient. The amnestic and disinhibiting effects mean that environment matters: use in safe, controlled settings reduces the risk of memory gaps during consequential situations.
Aftercare & integration. Lorazepam's amnestic properties mean that parts of the experience may be unrecoverable — this is normal, not a sign of brain damage. If memory gaps cause distress, writing down what is remembered soon after effects subside can help reconstruct the timeline.
Residual sedation and impaired coordination may persist for 12–24 hours after a dose. Avoid demanding cognitive or physical tasks the following day. Sleep architecture may be disrupted for 1–2 nights after use, even from a single dose.
Recovery & Support
Benzodiazepine dependence is a recognized medical condition with established treatment protocols. The standard approach is conversion to a long-acting benzodiazepine (typically diazepam) followed by a gradual dose taper over weeks to months. Abrupt cessation after chronic use is medically dangerous — seizures and delirium are possible.
Tapering should be supervised by a physician experienced in benzodiazepine withdrawal. Recovery from benzodiazepine dependence can involve a protracted withdrawal syndrome — symptoms including anxiety, insomnia, and sensory sensitivity may persist for months after the final dose. This is a documented neurological phenomenon, not a return of the original condition.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Slow or shallow breathing, blue-tinged lips or fingernails, unresponsiveness to voice or pain, and gurgling or snoring sounds while unconscious indicate a medical emergency. Confusion and heavy sedation alone are expected effects — breathing difficulty is the critical threshold.
Immediate steps:
- 1. Call emergency services immediately if breathing is slow, irregular, or has stopped
- 2. Place the person in the recovery position (on their side) to prevent choking if vomiting occurs
- 3. Do not leave the person alone
- 4. Do not attempt to induce vomiting
- 5. Monitor breathing continuously until help arrives
What to tell the dispatcher: Name the substance (lorazepam/Ativan), estimated amount taken, time of ingestion, and any other substances involved — especially opioids or alcohol. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agent: Flumazenil can reverse benzodiazepine effects in hospital settings but is not available over the counter. In people physically dependent on benzodiazepines, flumazenil can trigger dangerous withdrawal including seizures — its use requires medical supervision.
Legal Status[edit]
Legal status
Lorazepam is internationally controlled as a prescription medication with recognized abuse and dependence potential. It is scheduled under the United Nations Convention on Psychotropic Substances (1971) as a Schedule IV substance — the least restrictive tier of international control, reflecting accepted therapeutic utility balanced against dependence risk.[12] No jurisdiction permits unscheduled or over-the-counter availability.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule IV (Controlled Substances Act) | Prescription required; refill limits apply[12] |
| United Kingdom | Class C, Schedule 4 Part I (Misuse of Drugs Act 1971) | Prescription only; possession without prescription is an offense[30] |
| Canada | Schedule IV (Controlled Drugs and Substances Act) | Prescription required[12] |
| Australia | Schedule 4 (Prescription Only Medicine) | Remains S4; not rescheduled to S8 (unlike Alprazolam)[12] |
| International | Schedule IV (UN Convention on Psychotropic Substances, 1971) | Minimum international controls; national implementation varies[12] |
Individual EU member states schedule lorazepam under national drug control legislation. In Germany, it is marketed as Tavor under Betäubungsmittelgesetz prescribing requirements; in Spain, it is available as Orfidal under standard prescription controls. citation needed
references
- [1]
- [2]
- [3]
- [4]
- [5] ^abAlldredge BK, Gelb AM, Isaacs SM, Corry MD, Allen F, et al. (2001) A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus — The New England journal of medicine PMID:11547716
- [6] ^abcGlauser TA, Shinnar S, Gloss D, Alldredge BK, Arya R (2016) Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults — Epilepsy currents doi:10.5698/1535-7597-16.1.48